Schroder Investment Management Group Atea Pharmaceuticals, Inc. Transaction History

Schroder Investment Management Group

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$5.33 - $8.18 $558,525 - $857,174	-104,789 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$5.5 - $9.19 $7.9 Million - $13.2 Million	-1,436,317 Reduced 93.2%	104,789 $742,000
Q4 2021 Feb 14, 2022	BUY	$7.67 - $44.59 $11.7 Million - $68 Million	1,525,824 Added 9984.45%	1,541,106 $13.8 Million
Q2 2021 Aug 13, 2021	SELL	$19.22 - $59.08 $231,466 - $711,500	-12,043 Reduced 44.07%	15,282 $328,000
Q1 2021 May 17, 2021	BUY	$41.42 - $88.44 $1.13 Million - $2.42 Million	27,325 New	27,325 $1.69 Million

112

50.9M

900

63K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $262M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

Stay updated on Schroder Investment Management Group with notifications on news.